99 related articles for article (PubMed ID: 8593598)
1. Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol.
Fride E
Brain Res; 1995 Oct; 697(1-2):83-90. PubMed ID: 8593598
[TBL] [Abstract][Full Text] [Related]
2. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
Fride E; Barg J; Levy R; Saya D; Heldman E; Mechoulam R; Vogel Z
J Pharmacol Exp Ther; 1995 Feb; 272(2):699-707. PubMed ID: 7853184
[TBL] [Abstract][Full Text] [Related]
3. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
4. Developmental aspects of anandamide: ontogeny of response and prenatal exposure.
Fride E; Mechoulam R
Psychoneuroendocrinology; 1996 Feb; 21(2):157-72. PubMed ID: 8774060
[TBL] [Abstract][Full Text] [Related]
5. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
6. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
7. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
8. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
9. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
Fride E; Mechoulam R
Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
[TBL] [Abstract][Full Text] [Related]
11. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.
Wiley JL; Smith FL; Razdan RK; Dewey WL
Eur J Pharmacol; 2005 Mar; 510(1-2):59-68. PubMed ID: 15740725
[TBL] [Abstract][Full Text] [Related]
12. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
Romero J; de Miguel R; García-Palomero E; Fernández-Ruiz JJ; Ramos JA
Brain Res; 1995 Oct; 694(1-2):223-32. PubMed ID: 8974649
[TBL] [Abstract][Full Text] [Related]
13. Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice.
Fride E; Mechoulam R
Brain Res Dev Brain Res; 1996 Aug; 95(1):131-4. PubMed ID: 8873985
[TBL] [Abstract][Full Text] [Related]
14. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
15. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.
Thomas BF; Adams IB; Mascarella SW; Martin BR; Razdan RK
J Med Chem; 1996 Jan; 39(2):471-9. PubMed ID: 8558515
[TBL] [Abstract][Full Text] [Related]
17. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.
Weidenfeld J; Feldman S; Mechoulam R
Neuroendocrinology; 1994 Feb; 59(2):110-2. PubMed ID: 8127398
[TBL] [Abstract][Full Text] [Related]
18. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
[TBL] [Abstract][Full Text] [Related]
19. delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats.
Wickens AP; Pertwee RG
Eur J Pharmacol; 1993 Nov; 250(1):205-8. PubMed ID: 8119321
[TBL] [Abstract][Full Text] [Related]
20. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
